Logo image of TERN

TERNS PHARMACEUTICALS INC (TERN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TERN - US8808811074 - Common Stock

35.17 USD
+1.06 (+3.11%)
Last: 1/13/2026, 2:21:53 PM
Fundamental Rating

3

TERN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. TERN has a great financial health rating, but its profitability evaluates not so good. TERN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TERN has reported negative net income.
TERN had a negative operating cash flow in the past year.
In the past 5 years TERN always reported negative net income.
TERN had a negative operating cash flow in each of the past 5 years.
TERN Yearly Net Income VS EBIT VS OCF VS FCFTERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -31.31%, TERN perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
The Return On Equity of TERN (-33.24%) is better than 60.53% of its industry peers.
Industry RankSector Rank
ROA -31.31%
ROE -33.24%
ROIC N/A
ROA(3y)-26.35%
ROA(5y)-28.14%
ROE(3y)-27.6%
ROE(5y)-31.38%
ROIC(3y)N/A
ROIC(5y)N/A
TERN Yearly ROA, ROE, ROICTERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TERN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TERN Yearly Profit, Operating, Gross MarginsTERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

TERN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TERN has been increased compared to 5 years ago.
TERN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TERN Yearly Shares OutstandingTERN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TERN Yearly Total Debt VS Total AssetsTERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 102.49 indicates that TERN is not in any danger for bankruptcy at the moment.
TERN has a Altman-Z score of 102.49. This is amongst the best in the industry. TERN outperforms 98.42% of its industry peers.
There is no outstanding debt for TERN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 102.49
ROIC/WACCN/A
WACCN/A
TERN Yearly LT Debt VS Equity VS FCFTERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

TERN has a Current Ratio of 19.52. This indicates that TERN is financially healthy and has no problem in meeting its short term obligations.
TERN has a better Current ratio (19.52) than 88.95% of its industry peers.
A Quick Ratio of 19.52 indicates that TERN has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 19.52, TERN belongs to the best of the industry, outperforming 88.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 19.52
Quick Ratio 19.52
TERN Yearly Current Assets VS Current LiabilitesTERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.71% over the past year.
EPS 1Y (TTM)12.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TERN will show a decrease in Earnings Per Share. The EPS will decrease by -4.19% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.03%
EPS Next 2Y-8.81%
EPS Next 3Y-9.79%
EPS Next 5Y-4.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TERN Yearly Revenue VS EstimatesTERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
TERN Yearly EPS VS EstimatesTERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TERN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TERN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TERN Price Earnings VS Forward Price EarningsTERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TERN Per share dataTERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as TERN's earnings are expected to decrease with -9.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.81%
EPS Next 3Y-9.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TERN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TERNS PHARMACEUTICALS INC

NASDAQ:TERN (1/13/2026, 2:21:53 PM)

35.17

+1.06 (+3.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)03-18 2026-03-18/amc
Inst Owners78.95%
Inst Owner Change0.05%
Ins Owners0.22%
Ins Owner Change13.02%
Market Cap3.17B
Revenue(TTM)N/A
Net Income(TTM)-94.44M
Analysts84.71
Price Target54.63 (55.33%)
Short Float %14.87%
Short Ratio2.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.4%
Min EPS beat(2)10.7%
Max EPS beat(2)12.1%
EPS beat(4)4
Avg EPS beat(4)13.96%
Min EPS beat(4)8.96%
Max EPS beat(4)24.07%
EPS beat(8)8
Avg EPS beat(8)12.04%
EPS beat(12)10
Avg EPS beat(12)9.13%
EPS beat(16)14
Avg EPS beat(16)10.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)75.91%
PT rev (3m)198.91%
EPS NQ rev (1m)2.63%
EPS NQ rev (3m)1.53%
EPS NY rev (1m)-0.49%
EPS NY rev (3m)2.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.15
P/tB 11.15
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0
BVpS3.15
TBVpS3.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.31%
ROE -33.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.35%
ROA(5y)-28.14%
ROE(3y)-27.6%
ROE(5y)-31.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -0.71%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.52
Quick Ratio 19.52
Altman-Z 102.49
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)29.77%
Cap/Depr(5y)60.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.57%
EPS Next Y2.03%
EPS Next 2Y-8.81%
EPS Next 3Y-9.79%
EPS Next 5Y-4.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.92%
EBIT Next 3Y-16.74%
EBIT Next 5Y-9.07%
FCF growth 1Y-31.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.76%
OCF growth 3YN/A
OCF growth 5YN/A

TERNS PHARMACEUTICALS INC / TERN FAQ

Can you provide the ChartMill fundamental rating for TERNS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TERN.


What is the valuation status of TERNS PHARMACEUTICALS INC (TERN) stock?

ChartMill assigns a valuation rating of 0 / 10 to TERNS PHARMACEUTICALS INC (TERN). This can be considered as Overvalued.


How profitable is TERNS PHARMACEUTICALS INC (TERN) stock?

TERNS PHARMACEUTICALS INC (TERN) has a profitability rating of 1 / 10.


What is the financial health of TERNS PHARMACEUTICALS INC (TERN) stock?

The financial health rating of TERNS PHARMACEUTICALS INC (TERN) is 8 / 10.